Pfizer Inc is close to an agreement to buy Medivation Inc for about US$14 billion, people familiar with the situation said, the latest in a long run of blockbuster deals in the drug and biotechnology industries.
The deal could be announced as early as Monday next week, said the people, who asked not to be identified because the matter is still private. The biotech company’s shares closed at US$67.16 on Friday, giving it a market value of US$11.1 billion.
By acquiring Medivation, Pfizer would gain a blockbuster prostate-cancer treatment, Xtandi, that is already approved for sale in the US and elsewhere and that analysts project will generate US$1.33 billion in annual sales by 2020.
Photo: Bloomberg
Pfizer chief executive officer Ian Read said in May that he was more interested in acquiring late-stage assets because the company already had plenty of early-stage drugs in the works.
Pfizer spokeswoman Joan Campion declined to comment.
Medivation representatives did not immediately respond to telephone calls and e-mails requesting comment.
Pfizer has been relying on new branded treatments, including cancer drugs, to boost revenue, as sales of older medicines have slowed. In August, the New York-based company reported earnings that beat expectations after sales of breast cancer treatment Ibrance were better than analysts’ estimates.
A US$14 billion purchase of Medivation would be Pfizer’s biggest deal since buying Hospira Inc for about US$17 billion last year and the company is a rare prize.
As oncology becomes one of the hottest areas in drug development, large drug and biotechnology firms have found only a few mid-sized targets with revenue-generating, approved treatments.
Though Xtandi is a blockbuster, Pfizer will split US sales with Tokyo-based Astellas Pharma Inc, which partnered with Medivation on the drug.
Medivation also comes with two experimental products: a drug for breast cancer and another for the blood cancer lymphoma. The breast cancer drug belongs to a class of treatments known as PARP inhibitors, which disrupt cancer cells’ process of DNA repair.
The drug, talazoparib, could well be the most potent medicine in the PARP class, according to Katherine Xu, an analyst at William Blair & Co in New York, who estimates annual peak sales could reach US$3 billion.
By spurning Sanofi’s initial offer, valued at about US$9 billion, Medivation was able to bring in more potential suitors and drive up the bidding.
Gilead Sciences Inc, Celgene Corp and Amgen Inc were among the other drugmakers reported to consider the deal.
Medivation previously rejected French drugmaker Sanofi’s offer of US$58 a share, plus a contingent value right valued at a maximum of US$3 a share. The Financial Times reported earlier on Sunday that the Pfizer agreement was imminent.
The deal is a blow to Sanofi’s cancer ambitions. It has spent five months both courting and pressuring Medivation to reach a takeover agreement.
Sanofi chief executive officer Olivier Brandicourt might have pushed his case too aggressively. After Sanofi’s initial offer of US$52.50 a share was spurned, the Paris-based drugmaker chose to go straight to Medivation investors, seeking their support to oust the board.
Medivation warned of a “devil’s bargain” that would usher in new directors who might settle for a takeover price that was not in shareholders’ interest. Sanofi dropped the hostility last month as Medivation agreed to enter into confidentiality agreements.
‘SWASTICAR’: Tesla CEO Elon Musk’s close association with Donald Trump has prompted opponents to brand him a ‘Nazi’ and resulted in a dramatic drop in sales Demonstrators descended on Tesla Inc dealerships across the US, and in Europe and Canada on Saturday to protest company chief Elon Musk, who has amassed extraordinary power as a top adviser to US President Donald Trump. Waving signs with messages such as “Musk is stealing our money” and “Reclaim our country,” the protests largely took place peacefully following fiery episodes of vandalism on Tesla vehicles, dealerships and other facilities in recent weeks that US officials have denounced as terrorism. Hundreds rallied on Saturday outside the Tesla dealership in Manhattan. Some blasted Musk, the world’s richest man, while others demanded the shuttering of his
ADVERSARIES: The new list includes 11 entities in China and one in Taiwan, which is a local branch of Chinese cloud computing firm Inspur Group The US added dozens of entities to a trade blacklist on Tuesday, the US Department of Commerce said, in part to disrupt Beijing’s artificial intelligence (AI) and advanced computing capabilities. The action affects 80 entities from countries including China, the United Arab Emirates and Iran, with the commerce department citing their “activities contrary to US national security and foreign policy.” Those added to the “entity list” are restricted from obtaining US items and technologies without government authorization. “We will not allow adversaries to exploit American technology to bolster their own militaries and threaten American lives,” US Secretary of Commerce Howard Lutnick said. The entities
Minister of Finance Chuang Tsui-yun (莊翠雲) yesterday told lawmakers that she “would not speculate,” but a “response plan” has been prepared in case Taiwan is targeted by US President Donald Trump’s reciprocal tariffs, which are to be announced on Wednesday next week. The Trump administration, including US Secretary of the Treasury Scott Bessent, has said that much of the proposed reciprocal tariffs would focus on the 15 countries that have the highest trade surpluses with the US. Bessent has referred to those countries as the “dirty 15,” but has not named them. Last year, Taiwan’s US$73.9 billion trade surplus with the US
Prices of gasoline and diesel products at domestic gas stations are to fall NT$0.2 and NT$0.1 per liter respectively this week, even though international crude oil prices rose last week, CPC Corp, Taiwan (台灣中油) and Formosa Petrochemical Corp (台塑石化) said yesterday. International crude oil prices continued rising last week, as the US Energy Information Administration reported a larger-than-expected drop in US commercial crude oil inventories, CPC said in a statement. Based on the company’s floating oil price formula, the cost of crude oil rose 2.38 percent last week from a week earlier, it said. News that US President Donald Trump plans a “secondary
RSS